Optiray 350 and Obstruction of the ureteropelvic junction - a phase IV clinical study of FDA data
We study 1,473 people who take Optiray 350 or have Obstruction of the ureteropelvic junction. No report of Obstruction of the ureteropelvic junction is found in people who take Optiray 350.
The phase IV clinical study is created by eHealthMe based on reports from the FDA, and is updated regularly.
Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.
No report is found.
What is Optiray 350?
Optiray 350 has active ingredients of ioversol. eHealthMe is studying from 1,470 Optiray 350 users for its effectiveness, alternative drugs and more.
What is Obstruction Of The Ureteropelvic Junction?
Obstruction of the ureteropelvic junction: no further information found.
Do you take Optiray 350 and have Obstruction of the ureteropelvic junction?Check whether Obstruction of the ureteropelvic junction is associated with a drug or a condition
How to use the study?
You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.
How severe was Obstruction of the ureteropelvic junction and when was it recovered:
Expand to all the drugs that have ingredients of ioversol:
Alternative drugs to, pros and cons of Optiray 350:
- Optiray 350 (1,470 reports)
Obstruction of the ureteropelvic junction treatments and more:
- Obstruction of the ureteropelvic junction (3 reports)
COVID vaccines that are related to Obstruction of the ureteropelvic junction:
- Obstruction of the ureteropelvic junction in Moderna COVID Vaccine
- Obstruction of the ureteropelvic junction in Pfizer BioNTech Covid Vaccine
- Obstruction of the ureteropelvic junction in Johnson and Johnson Covid Vaccine
All the drugs that are associated with Obstruction of the ureteropelvic junction:
All the conditions that are associated with Obstruction of the ureteropelvic junction:
How the study uses the data?
The study uses data from the FDA. It is based on ioversol (the active ingredients of Optiray 350) and Optiray 350 (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
Who is eHealthMe?
With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Mircera and Paleness - a second ago
- Flecainide Acetate and Varicocele - 2 seconds ago
- Alphagan and Hepatic Encephalopathy - 4 seconds ago
- Actos and Paraesthesia - 6 seconds ago
- Avandia and Avapro drug interaction - 7 seconds ago
- Xeloda and Paraplatin drug interaction - 11 seconds ago
- Stiolto Respimat and Drug Resistance - 22 seconds ago
- Pulmozyme and Secretion Discharge - 23 seconds ago
- Valerian and Tivicay drug interaction - 27 seconds ago
- Norepinephrine Bitartrate and Cephalexin drug interaction - 33 seconds ago